Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $36 from $35 and keeps an Outperform rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Harmony Biosciences Holdings: Strong Financial Performance and Positive Outlook Drive Buy Rating
- Harmony Biosciences raises FY25 revenue view to $845M-$865M from $820M-$860M
- Harmony Biosciences reports preliminary Q3 Wakix revenue $239M
- Harmony Biosciences price target lowered to $43 from $50 at UBS